What Bristol and Celldex's Team-Up Means for Investors
Bristol Myers-Squibb and Celldex agreed to team up in a phase 1/2 study combining nivolumab (Bristol's PD-1 immuno-oncology candidate) and varlilumab. The study will cover several tumor types, potentially including metastatic melanoma, colorectal, ovarian, and non-small cell lung cancer. Bristol paid $5 million up front for the trial and is also splitting the costs of conducting the trial with Celldex. Bristol also gains the right of first negotiation if Celldex decides to license varlilumab.
In this video, from Wednesday's Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson look at the partnership and the potential benefits for both parties.
Can Bristol and Celldex keep up with this top stock?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article What Bristol and Celldex's Team-Up Means for Investors originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.